Jnj-101556143
Phase 2
Johnson & JohnsonJnj-101556143 is one of 9 therapeutic programs targeting Prostatic Neoplasms. It is currently in Phase 2.
1
Indications
4
Total Trials
4
Active Trials
8
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
9 competitors in Prostatic Neoplasms
#DrugCompanyPhaseTrials
1Erleada
Johnson & JohnsonApproved
Zytiga
Johnson & JohnsonPhase 3
Xtandi
AstellasPhase 3
Verzenio
Eli LillyPhase 3
Androgen Deprivation Therapy
Johnson & JohnsonPhase 3
Prednisone or Prednisolone
Johnson & JohnsonPhase 3
Trelstar
OOncoVerity, Inc.
Phase 2
Jnj-101556143
Johnson & JohnsonPhase 2
JNJ-78278343
Johnson & JohnsonPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostatic Neoplasms3 trials
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Jnj-101556143. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]
- Company